Your session is about to expire
← Back to Search
Investigational Imaging Technique for Brain Cancer
N/A
Waitlist Available
Led By Jeffrey J. Olson, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new imaging technique to see if it is safe and reliable for finding brain tumors and their margins during surgery.
Who is the study for?
This trial is for adults (18+) who need brain surgery within the next 14 days for a new or worsening glioblastoma, astrocytoma, or oligodendroglioma. Participants must understand the study's nature and agree to its procedures. Those only needing a needle biopsy or with serious health issues like uncontrolled infection, heart problems, or mental illness that could limit compliance are excluded.
What is being tested?
The trial tests a new imaging technique called quantitative oblique back-illumination microscopy (qOBM) during brain surgery. It aims to safely and reliably identify tumor edges in patients undergoing craniotomy—a surgical procedure to remove part of the skull to access the brain.
What are the potential side effects?
Since qOBM is an imaging technique used during surgery rather than a drug, it may not have typical side effects. However, risks may include potential complications from extended surgery time if qOBM prolongs the procedure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Adverse Events
Reliability of Quantitative Oblique Back Illumination Microscopy Device Determined by Central Tendency
Poisoning, Illuminating Gas
+2 moreSecondary study objectives
Microscopy
Back
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (qOBM)Experimental Treatment2 Interventions
Patients undergo craniotomy with intraoperative ex vivo and in situ tumor assessment with qOBM. Patients then undergo postoperative exam with CT or MRI any of days 1-5 after surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Craniotomy
2016
N/A
~740
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,112,063 Total Patients Enrolled
Emory UniversityLead Sponsor
1,708 Previous Clinical Trials
2,607,460 Total Patients Enrolled
Jeffrey J. Olson, MDPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute
6 Previous Clinical Trials
27 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am only having a needle biopsy.My surgery is scheduled within the next 14 days.I need surgery to remove a brain tumor.I have signed a consent form understanding my cancer, the study, and its risks and benefits.I am 18 years old or older.I have a new or worsening brain tumor that needs surgery.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (qOBM)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.